We found dinaciclib and combination treatment of MV4-11, MOLM-13, and OCI-AML3 AML cell lines decreased total, phosphorylated, and non-phosphorylated “active” β-catenin protein levels as measured by immunoblots (Fig. 2C). This evidence concerns the gene RUNX2 and acute myeloid leukemia.